LOS ALTOS, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the issuance of U.S. Patent No. 12,036,211 by the United States Patent and Trademark Office (USPTO) for UNI-494.

加利福尼亚州洛斯阿尔托斯，2024年7月17日（环球通讯社）--Unicycive Therapeutics，Inc.（纳斯达克：UNCY），一家临床阶段的生物技术公司，为肾病患者开发治疗（“公司”或“Unicycive”），今天宣布美国专利商标局（USPTO）为UNI-494发布了美国专利12036211号。

The patent, valid until 2040, secures protection of a method of treating a disease or a condition selected from acute kidney injury or contrast induced nephropathy by administering the UNI-494 compound. The UNI-494 compound covered in the method of use claims is not limited to a particular salt, dose or type of administration. UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator.

该专利有效期至2040年，通过服用UNI-494化合物，确保了对从急性肾损伤或造影剂肾病中选择的疾病或病症的治疗方法的保护。使用方法权利要求中涵盖的UNI-494化合物不限于特定的盐，剂量或给药类型。。

Mitochondrial dysfunction plays a critical role in the progression of acute kidney injury and chronic kidney disease. 'We are pleased to receive this patent from the USPTO, which ensures intellectual property protection for many years to come,” said Shalabh Gupta, MD, Chief Executive Officer of Unicycive.

线粒体功能障碍在急性肾损伤和慢性肾脏疾病的进展中起着至关重要的作用。”Unicycive首席执行官Shalabh Gupta医学博士说：“我们很高兴收到USPTO的这项专利，它确保了未来多年的知识产权保护。”。

“This Method of Use patent for UNI-494 is an important component of our strategy to become a leader in the development of drugs that target kidney disease. UNI-494 is currently in an ongoing Phase 1 clinical trial and recently received Orphan Drug Designation in Delayed Graft Function, a form of acute kidney injury.

“UNI-494的这种使用方法专利是我们成为针对肾脏疾病药物开发领导者的战略的重要组成部分。UNI-494目前正在进行1期临床试验，最近在延迟移植功能（一种急性肾损伤）中获得了孤儿药指定。

This patent helps protect our approach and expands our portfolio as we look to develop novel treatments for kidney diseases.” About UNI-494 UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator. Mitochondrial dysfunction plays a critical role in the progression of acute kidney injury and chronic kidney.

这项专利有助于保护我们的方法，并扩大我们的投资组合，因为我们希望开发新的肾脏疾病治疗方法。”关于UNI-494 UNI-494是一种新型烟酰胺酯衍生物和选择性ATP敏感的线粒体钾通道激活剂。线粒体功能障碍在急性肾损伤和慢性肾的进展中起关键作用。